Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
The ongoing collaboration between SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE: CWY) resulted in the Tuesday filing of three patent applications under the International Patent Cooperation Treaty.
ScisPARC Ltd.（納斯達克股票代碼：SPRC）和Clearmind Medicine Inc.（納斯達克股票代碼：CMND）（CSE: CMND）（FSE: CWY）之間的持續合作導致週二根據《國際專利合作條約》提交了三項專利申請。
SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system and Clearmind, a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, jointly announced that the three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide.
專注於開發治療中樞神經系統疾病和罕見疾病的療法的臨床階段專業製藥公司ScisPARC和專注於發現和開發新型迷幻衍生療法的生物技術公司Clearmind共同宣佈，這三項專利申請涉及麥角酸二乙酰胺（LSD）、迷幻藥、N、N-二甲基色胺（DMT）的新型專有組合以及棕櫚酰乙醇胺（PEA），後者是ScisPARC專有CannaMide的活性成分。
The patents seek to protect the companies' psychedelic compound combinations, ensuring exclusive rights to their innovative therapies. This move aims to solidify their market position, attract investments and drive the advancement of psychedelic medicine for mental health treatment.
這些專利旨在保護兩家公司的迷幻化合物組合，確保其創新療法的專有權。此舉旨在鞏固他們的市場地位，吸引投資並推動用於心理健康治療的迷幻醫學的發展。
These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
這些申請以前是由Clearmind作爲臨時專利申請向美國專利商標局提交的。
Executive Insights On Strategic Expansion
高管對戰略擴張的見解
"We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc's CEO, Oz Adler. "We believe in the added value that CannAmide can offer when combined with various psychedelic compounds that are known for their therapeutic advantages."
ScisPARC首席執行官奧茲·阿德勒表示：“我們很高興通過擴大知識產權投資組合，繼續與Clearmind進行持續合作，這是一項重要的資產。”“我們相信，CannaMide與各種以其治療優勢而聞名的迷幻化合物結合時可以提供附加價值。”
SPRC And CMND Price Action
SPRC 和 CMND 價格走勢
SPRC's shares were trading 2.74% higher at $4.13 per share and CMND's shares were trading 7.79% lower at $1.42 per share at the time of this writing around 10 AM ET Wednesday.
截至美國東部時間週三上午10點左右，SPRC的股價上漲2.74％，至每股4.13美元，CMND的股價下跌7.79％，至每股1.42美元。
Related News
相關新聞
- What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?
- Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
- 迷幻藥物開發商 ScisPARC 和 Clearmind 股票怎麼了？
- Psyched：迷幻藥與性、搖頭丸和聯邦政府的批准、加拿大人的臨終護理等等
Photo: Benzinga edit with photo by Photon photo and Jynto on Wikimedia Commons.
照片：Benzinga 在維基共享資源上用 Photon photo 和 Jynto 的照片進行編輯。
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
本辛加大麻資本會議將於2024年4月16日和17日在佛羅里達州好萊塢的新地點重返佛羅里達州。在外交官海灘度假村舉行的爲期兩天的活動將爲大小企業家提供交流、學習和成長的機會。這次會議以其引領潮流的能力和對大麻未來的影響而聞名，記住你的日曆——這是大麻界年度必去的活動。
Get your tickets now on bzcannabis.com – Prices will increase very soon!
立即購買門票 bzcannabis.com — 價格會漲得很厲害開啓！